LIFRENZAL
Dead / Abandoned — Abandoned — no statement of use filed (as of 15 Aug 2022)
What this means for you
This application is over — abandoned 15 Aug 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88229099
- Mark type
- Stylized text
- Filed
- 13 Dec 2018
- Published for opposition
- 14 May 2019
- Abandoned
- 15 Aug 2022
- Attorney of record
- Chelsea E. Carbone
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in in pediatric, geriatric, emergency, family, and human preventative medicine; Pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease
- Class 042 — Scientific and technological services: Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases
Owner
- AADi Bioscience, Inc., Pacific Palisades, CA, US
- AADi Bioscience, Inc., Pacific Palisades, CA, US
Prosecution history
- 15 Aug 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 15 Aug 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 15 Jan 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Jan 2022 — SOU EXTENSION 5 GRANTED
- 06 Jan 2022 — SOU EXTENSION 5 FILED
- 14 Jan 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 06 Jan 2022 — SOU TEAS EXTENSION RECEIVED
- 09 Jul 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jul 2021 — SOU EXTENSION 4 GRANTED
- 07 Jul 2021 — SOU EXTENSION 4 FILED
- 07 Jul 2021 — SOU TEAS EXTENSION RECEIVED
- 05 Jan 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Dec 2020 — SOU EXTENSION 3 GRANTED
- 31 Dec 2020 — SOU EXTENSION 3 FILED
- 31 Dec 2020 — SOU TEAS EXTENSION RECEIVED